Abstract
For several years, the identification of molecular sequencing alterations has considerably changed the perception and treatment of non-small cell lung cancer (NSCLC). These alterations have been defined as "driver mutations", such as mutations in EGFR and EML4-ALK fusion gene, and are highly sensitive to specific therapies. Other targets have also been identified recently. Personalized medicine is now a reality for patients with advanced NSCLC on the basis of routine screening for EGFR, HER2, KRAS, BRAF, PI3KCA mutations and EML4-ALK rearrangement. This article describes identified biomarkers, available targeted therapies, and the main clinical research approaches in NSCLC.
Keywords:
Biomarkers; Biomarqueurs; Cancer bronchique non à petites cellules; Lung cancer; Targeted therapy; Thérapies ciblées.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.
MeSH terms
-
Anaplastic Lymphoma Kinase
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Biomarkers, Tumor / analysis
-
Biomarkers, Tumor / genetics
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / genetics
-
Carcinoma, Non-Small-Cell Lung / pathology
-
ErbB Receptors / antagonists & inhibitors
-
ErbB Receptors / genetics
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / genetics
-
Lung Neoplasms / pathology
-
Molecular Targeted Therapy / methods*
-
Molecular Targeted Therapy / trends*
-
Precision Medicine
-
Protein Kinase Inhibitors / therapeutic use
-
Receptor Protein-Tyrosine Kinases / antagonists & inhibitors
-
Receptor Protein-Tyrosine Kinases / genetics
Substances
-
Biomarkers, Tumor
-
Protein Kinase Inhibitors
-
ALK protein, human
-
Anaplastic Lymphoma Kinase
-
EGFR protein, human
-
ErbB Receptors
-
Receptor Protein-Tyrosine Kinases